Report for: A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial

Title	A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial
Published in	Trials, February 2021
DOI	10.1186/s13063-021-05072-4
Pubmed ID	33546739
Authors	G. Moreno-González, A. Mussetti, A. Albasanz-Puig, I. Salvador, A. Sureda, C. Gudiol, R. Salazar, M. Marin, M. Garcia, V. Navarro, I. de la Haba Vaca, E. Coma, G. Sanz-Linares, X. Dura, S. Fontanals, G. Serrano, C. Cruz, R. Mañez

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Spain	3	50%
Unknown	3	50%

Type	Count	As %
Members of the public	4	67%
Practitioners (doctors, other healthcare professionals)	2	33%

Mendeley readers

The data shown below were compiled from readership statistics for 450 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	450	100%

Readers by professional status	Count	As %
Student > Bachelor	58	13%
Student > Master	44	10%
Researcher	32	7%
Student > Doctoral Student	26	6%
Other	20	4%
Other	71	16%
Unknown	199	44%

Readers by discipline	Count	As %
Medicine and Dentistry	120	27%
Nursing and Health Professions	36	8%
Psychology	14	3%
Pharmacology, Toxicology and Pharmaceutical Science	13	3%
Social Sciences	8	2%
Other	48	11%
Unknown	211	47%

A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a…